Currently Viewing:
The American Journal of Managed Care November 2014
The Correlation of Family Physician Work With Submitted Codes and Fees
Richard Young, MD, and Tiffany L. Overton, MPH
Population Targeting and Durability of Multimorbidity Collaborative Care Management
Elizabeth H.B. Lin, MD, MPH; Michael Von Korff, ScD; Do Peterson, MS; Evette J. Ludman, PhD; Paul Ciechanowski, MD, MPH; and Wayne Katon, MD
Have Prescription Drug Brand Names Become Generic?
Alfred B. Engelberg, JD
Will Medicare Advantage Payment Reforms Impact Plan Rebates and Enrollment?
Lauren Hersch Nicholas, PhD, MPP
Variation in Hospital Inpatient Prices Across Small Geographic Areas
Jared Lane K. Maeda, PhD, MPH; Rachel Mosher Henke, PhD; William D. Marder, PhD; Zeynal Karaca, PhD; Bernard S. Friedman, PhD; and Herbert S. Wong, PhD
Medical Cost Burdens Among Nonelderly Adults With Asthma
Emily Carrier, MD, and Peter Cunningham, PhD
The Role of Retail Pharmacies in CVD Prevention After the Release of the ATP IV Guidelines
William H. Shrank, MD, MSHS; Andrew Sussman, MD; and Troyen A. Brennan, MD, JD
Care Coordination Measures of a Family Medicine Residency as a Model for Hospital Readmission Reduction
Wayne A. Mathews, MS, PA-C
Medication Adherence and Readmission After Myocardial Infarction in the Medicare Population
Yuting Zhang, PhD; Cameron M. Kaplan, PhD; Seo Hyon Baik, PhD; Chung-Chou H. Chang, PhD; and Judith R. Lave, PhD
Reasons for Emergency Department Use: Do Frequent Users Differ?
Kelly M. Doran, MD, MHS; Ashley C. Colucci, BS; Stephen P. Wall, MD, MS, MAEd; Nick D. Williams, MA, PhD; Robert A. Hessler, MD, PhD; Lewis R. Goldfrank, MD; and Maria C. Raven, MD, MPH
Switching from Multiple Daily Injections to CSII Pump Therapy: Insulin Expenditures in Type 2 Diabetes
Guy David, PhD; Max Gill, MBA, Candace Gunnarsson, EdD; Jeff Shafiroff, PhD; and Steven Edelman, MD
Currently Reading
Service Setting Impact on Costs for Bevacizumab-Treated Oncology Patients
Nicole M. Engel-Nitz, PhD; Elaine B. Yu, PharmD, MS; Laura K. Becker, MS; and Art Small, MD

Service Setting Impact on Costs for Bevacizumab-Treated Oncology Patients

Nicole M. Engel-Nitz, PhD; Elaine B. Yu, PharmD, MS; Laura K. Becker, MS; and Art Small, MD
For patients with lung or colorectal cancer, bevacizumab treatment patterns and healthcare costs varied by the setting of treatment initiation (physician office vs hospital outpatient).
ABSTRACT
Objectives
To investigate treatment patterns and healthcare costs of patients with metastatic colorectal cancer (mCRC) or lung cancer (LC) who were treated with bevacizumab in a physician office (OFF) setting versus a hospital outpatient (HOP) setting.

Study Design
Retrospective analysis of claims from a national US health plan.

Methods
mCRC and LC patients initiating treatment with bevacizumab (index date) between January 1, 2006, and July 31, 2012, were identified. Patients were aged ≥18 years with ≥6-month pre- (baseline) and ≥6-month post index (follow-up) data, retaining patients who died with <6 months of follow-up. Differences by site of service were analyzed by χ2 and t test (bevacizumab administrations, dose) and general linear model adjusted for demographic and clinical characteristics (all-cause healthcare costs).

Results
A total of 1687 mCRC (OFF: 1292; HOP: 395) and 1232 LC patients (OFF: 983; HOP: 249) were identified. Mean age was 61.3 years, 56.3% were male, and 78% were treated in OFF. Treatment in OFF declined from 2006 (84% of patients) to 2012 (61%). For OFF versus HOP, mean length of treatment (208.3 vs 191.0 days; P = .007), number of bevacizumab administrations per month (1.4 vs 1.1; P <.001), and mean weekly dose (eg, for 2012, 4.34 vs 3.11 mg/kg, P <.05) were higher in OFF. Adjusted monthly HOP costs (vs OFF) were higher by 37.8% for mCRC patients (cost ratio = 1.378; 95% CI, 1.282-1.482) and 31.1% for LC patients (cost ratio = 1.311; 95% CI, 1.204-1.427)

Conclusions
Despite fewer administrations and lower weekly dose of bevacizumab in HOP, adjusted total costs were 31% to 38% higher for mCRC and LC patients treated in the HOP setting.

Am J Manag Care. 2014;20(11):e515-e522
This study assessed bevacizumab treatment patterns and healthcare costs for patients with lung or colorectal cancer by setting of treatment initiation.
  • Between 2006 and 2012, an increasing proportion of patients initiated treatment in hospital outpatient facilities rather than physician offices.
  • The number of administrations and weekly doses were generally lower in hospital outpatient settings, yet healthcare costs were higher than in physician office settings.
  • The shift in treatment setting for bevacizumab runs counter to programs attempting to retain patients in lower-intensity/lower-cost settings; these programs may need to account for the impact of market consolidation, reimbursement, and patient population changes.
Cancer treatment has evolved considerably in the last 2 decades with the introduction of biological agents that target molecular pathways and improved surgical and radiation techniques.1-3 There were an estimated 13.7 million cancer survivors in the United States in 2012 with a projection of 18 million by 2022.4 Assuming only a 2% annual increase in medical costs in the first year after diagnosis and in the last year of life, the direct costs of cancer care based on Medicare claims are estimated to rise from $125 billion in 2010 to $173 billion in 2020.5

Controlling rising healthcare costs is a national priority. Medicare price reforms beginning in 2003 have effectively lowered reimbursement rates for physician-administered drugs, which are primarily chemotherapy agents.6 Chemotherapy is a key treatment modality for many cancers, and patients typically receive chemotherapy in either a physician office setting or a hospital outpatient clinic. However, disparities in the acquisition costs of chemotherapy drugs—and thus, the income to providers—may have unintended consequences. 7 Hospitals eligible under the 340B program can obtain chemotherapy and other drugs at prices discounted up to 20% to 50%,8 while community-based oncology clinics are not eligible for discounts.7 Originally intended to assist hospitals serving vulnerable patients, 340B entities can obtain discounts on drugs for all eligible patients regardless of their insurance status or income.7 The percentage of hospitals participating in 340B programs nearly tripled between 2005 and 2011.8 A recent survey of community-based oncology practices suggests that some practices are closing,9 referring patients to hospital outpatient clinics,10 or being acquired or otherwise managed by a hospital entity.9 The impact of a potential shift in site of chemotherapy administration warrants investigation to understand the economic implications.

There is a dearth of published literature comparing treatment patterns and costs in hospital outpatient versus physician office settings. Privately commissioned studies suggest that the cost of cancer care is higher in hospital outpatient clinics.11,12 While these results provide an important overview of potential differences in costs depending on setting of chemotherapy administration, the studies did not control for important drivers of cost. For example, the selection of chemotherapy regimen is a function of multiple factors, including cancer type, stage, and patient clinical characteristics, and the cost of care will vary by regimen.

To investigate potential cost differences by site of administration, we focused on 2 of the most costly cancers: colorectal cancer and lung cancer,5 and the use of bevacizumab13 in the chemotherapy regimen. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor and is approved for metastatic colorectal cancer and nonsquamous nonsmall cell lung cancer. The objective of this study was to investigate treatment patterns and costs of patients with metastatic colorectal cancer (mCRC) or lung cancer (LC) who were treated with bevacizumab in a physician office (OFF) setting versus a hospital outpatient (HOP) setting.

METHODS

Data Source and Design


This retrospective study used data from a large US healthcare claims database from July 1, 2005, through July 31, 2012 (patients were identified during the period January 1, 2006, through March 31, 2012, and the baseline period was the 6 months prior). Medical claims include International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, Current Procedural Terminology procedure codes, Healthcare Common Procedure Coding System (HCPCS) procedure codes, site of service codes, provider specialty codes, and paid amounts. Pharmacy claims contain outpatient prescription pharmacy services including drug name, dosage form, drug strength, fill date, and dates of supply. Patients who died during the study were identified, and date of death was estimated based on a combination of hospital discharge status from medical claims, and month and year from the Social Security Administration master death file. Data were de-identified and accessed in accordance with Health Insurance Portability and Accountability Act privacy guidelines.14

Patients and Cohort Definition

Commercial and Medicare Advantage health plan members with medical and pharmacy benefits and evidence of bevacizumab treatment for either mCRC or LC were included. The index date was the earliest date of a claim for bevacizumab on or after January 1, 2006. Inclusion required: a) 2 claims (medical or facility claim) indicating receipt of bevacizumab (HCPCS codes C9214, C9257, J9035, S0116, Q2024) between January 1, 2006, and July 31, 2012; b) evidence of mCRC or LC; c) aged ≥18 years on the index date; and d) continuous enrollment for ≥6 months prior to the index date (baseline) and ≥6 months after the index date (followup). Patients with <6 months of follow-up due to death were included.

Evidence of mCRC required ≥2 claims with a diagnosis of colorectal cancer (CRC), ICD-9-CM 153.xx, 154.0, 154.1x, 154.8x, at least 30 days apart between 6 months prior to the index date (as early as July 1, 2005) and end of the study or health plan enrollment (as late as March 31, 2012), and ≥2 medical claims with a diagnosis of the same distant metastatic diagnoses (ICD-9-CM 196.0, 196.1, 196.3-196.9, 197.0-197.3, 197.7, 198.xx) at least 30 days apart during the same time period. Evidence of LC required ≥2 claims with a diagnosis of LC (ICD-9-CM 162.2-162.9) at least 30 days apart between 6 months before the index date and end of the study or health plan enrollment. Patients with claims for bevacizumab during baseline from an ophthalmology provider or >1 site of service (ie, physician office and hospital outpatient settings) were excluded. Patients with evidence of a primary cancer other than the index cancer (LC or CRC) were excluded if they had ≥2 claims for the same cancer type at least 30 days apart (based on 3-digit ICD-9-CM codes in the range 140.xx-195.xx, 199.xx-209.xx, excluding the codes for the index cancer type [LC or CRC and mCRC]). Patients with mCRC and evidence of another primary cancer were not excluded if the patient had a metastatic code for the same location (eg, if a patient had metastatic codes for the liver, the patient was not excluded if they also had a code for primary liver cancer).15 Study cohorts were established based on site of service codes where bevacizumab was administered: OFF or HOP.

MEASURES

Patient baseline characteristics included age (on index date), gender, insurance type, US census region, Quan-Charlson comorbidity score,16 and presence of metastatic disease. Outcomes were determined during an episode of care (EOC) which began on the first bevacizumab infusion and ended at the earliest of: a) 30 days after the last infusion that occurred prior to a treatment gap of ≥3 months; b) death; c) disenrollment from the health plan; or d) end of the study (July 31, 2012). Outcomes were: number of bevacizumab infusions, the average weekly weight-based dose of bevacizumab (mg/kg/week), duration of therapy, all-cause monthly healthcare costs, and total costs on the day of bevacizumab infusion. The weight-based dose was estimated by dividing the weekly dose administered by the disease-specific population average weights for patients enrolled in clinical trials (data on file, Genentech, Inc). Duration of therapy was defined as the length of the EOC; discontinuation was a bevacizumab treatment gap of ≥3 months following the last infusion. Monthly healthcare costs were computed from the sum of health plan-paid and patient-paid amounts for medical and pharmacy claims. Medical costs were calculated by location of service on the claim, including office visits, hospital outpatient visits, emergency service,inpatient stays, and other costs. Costs per infusion day were computed from the sum of costs related to chemotherapy infusion on each day of bevacizumab administration, and included all drug and drug administration costs. Costs were adjusted to 2012 dollars using the annual medical care component of the Consumer Price Index.17

Statistical Analyses

Differences between the OFF and HOP cohorts for all measures were analyzed by χ2 test (proportions) or 2-sided t test (continuous variables). The likelihood of discontinuation of therapy was modeled by Cox proportional hazards, and all-cause healthcare costs were modeled by a generalized linear model using a gamma distribution with a log link.18 The models for the combined mCRC and LC population were adjusted for age, baseline Quan-Charlson comorbidity score,15 and cancer type (mCRC or LC). Each cancer was modeled separately and contained the same adjustment variables except that cancer type was excluded.

RESULTS

Patient Selection and Characteristics


A total of 20,213 patients with at least 1 claim for bevacizumab during follow-up and no claims during baseline were identified (Figure 1). After applying inclusion and exclusion criteria, the final mCRC and LC study groups represented 1687 and 1232 patients, respectively. The most common reason for exclusion was lack of continuous health plan enrollment (n = 8524).

At baseline, the mean (SD) age of patients was 61.3 (11.2) years, 56.3% were men, and the mean (SD) comorbidity score was 6.62 (1.97) (Table 1). Study cohorts were similar for these characteristics. A higher proportion of HOP patients had evidence of metastatic disease at baseline than OFF patients. The majority of patients had commercial insurance but a higher proportion of LC patients had Medicare insurance versus commercial insurance in the HOP cohort.

Treatment Patterns

Over the entire study, the majority of mCRC (76.6%) and LC (79.8%) patients were treated in OFF settings (Figure 2). There was a pattern of an increasing proportion of patients treated at HOP sites over the course of the study for both mCRC and LC. The EOC was longer in the OFF vs HOP setting for mCRC patients (224.3 days vs 186.6 days, P <.001) but did not differ significantly for LC patients (187.3 days vs 197.9 days, P = .34) (Table 2). The number of bevacizumab infusions per EOC was greater at OFF sites than HOP sites for both mCRC (12.0 vs 7.5, P <.001) and LC (7.9 vs 6.9, P = .024). A similar pattern of significantly higher bevacizumab infusions per month was evident for both cancers at OFF versus HOP sites (P <.001). The mean weekly dose of bevacizumab on an estimated body weight basis (mg/kg) was significantly higher in the OFF setting for 3 of the 7 index years, and a similar trend was evident in all other years; mean weekly dose in the OFF setting ranged from 3.63 mg/kg in 2006 to 4.34 mg/kg in 2012, compared with 2.92 mg/kg in 2006 to 3.11 mg/kg in 2012 for the HOP setting (P <.05 in 2006, 2007, 2012, data not shown).

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up